Logo     Print Page  Close Window


News Release


Fibrocell to Present at Rodman & Renshaw 19th Annual Global Investment Conference and Global Genes’ 2017 RARE Patient Advocacy Summit

EXTON, Pa., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced that John Maslowski, President and Chief Executive Officer, will present at the Rodman & Renshaw 19th Annual Global Investment Conference on Monday, September 11 at 9:10 a.m. EDT in New York City.  In addition, Mr. Maslowski will participate in a panel discussion at the Global Genes’ RARE Patient Advocacy Summit on Thursday, September 14 at 3:15 p.m. PDT in Irvine, CA.

A live webcast of Fibrocell’s presentation at the Rodman & Renshaw Global Investment Conference will be available under the investor relations section of the Company’s website at www.fibrocell.com/investors/events and archived for 30 days. Please visit Fibrocell’s website several minutes prior to the start of the broadcasts to ensure adequate time for any software download that may be necessary.

About Fibrocell   

Fibrocell is an autologous cell and gene therapy company translating personalized biologics into medical breakthroughs for diseases affecting the skin and connective tissue.  Fibrocell’s most advanced product candidate, FCX-007, is the subject of a Phase 1/2 clinical trial for the treatment of recessive dystrophic epidermolysis bullosa. Fibrocell is in pre-clinical development of FCX-013, its product candidate for the treatment of moderate to severe localized scleroderma.  Fibrocell’s gene therapy portfolio is being developed in collaboration with Intrexon Corporation (NYSE: XON), a leader in synthetic biology.  For more information, visit http://www.fibrocell.com or follow Fibrocell on Twitter at @Fibrocell.

Trademarks  

Fibrocell, the Fibrocell logo and Fibrocell Science are trademarks of Fibrocell Science, Inc. and/or its affiliates.  All other names may be trademarks of their respective owners.

Investor & Media Relations Contact:
Karen Casey
484.713.6133
kcasey@fibrocell.com

Primary Logo

Fibrocell Science, Inc.